Literature DB >> 2649372

Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma?

D E Bergsagel1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2649372     DOI: 10.1016/0277-5379(89)90001-1

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


× No keyword cloud information.
  5 in total

1.  Do new therapeutic approaches (autotransplants, thalidomide, dexamethasone) improve the survival of patients with multiple myeloma followed in a rheumatology department?

Authors:  S El Mahou; M Attal; B Jamard; A Constantin; A Cantagrel; B Mazières; C Arnaud; M Laroche
Journal:  Clin Rheumatol       Date:  2005-11-23       Impact factor: 2.980

2.  Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment.

Authors:  L M Knudsen; T Rasmussen; L Jensen; H E Johnsen
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

Review 3.  Multiple myeloma. New treatment options.

Authors:  L Camba; B G Durie
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

4.  Multi-drug combination therapy with vincristine-melphalan-cyclophosphamide-prednisolone was more effective than cyclophosphamide-prednisolone in stage III myeloma. The Nagoya Myeloma Cooperative Study Group.

Authors:  K Shimizu; O Kamiya; N Hamajima; H Mizuno; M Kobayashi; N Hirabayashi; H Takeyama; R Kato; K Kawashima; M Nitta
Journal:  Jpn J Cancer Res       Date:  1990-12

5.  Posttreatment M-protein nadir level is a significant prognostic factor associated with survival in multiple myeloma. Nagoya Myeloma Cooperative Study Group.

Authors:  K Shimizu; O Kamiya; N Hirabayashi; A Ichikawa; K Kawashima; M Kobayashi; H Mizuno; E Nagura; M Nitta; H Saito; H Sao; T Shibata; H Takeyama
Journal:  Jpn J Cancer Res       Date:  1999-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.